<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132702">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01749878</url>
  </required_header>
  <id_info>
    <org_study_id>R1500-HV-1214</org_study_id>
    <nct_id>NCT01749878</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Tolerability of Single Doses of REGN1500</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1, first-in-human, randomized, ascending single-dose, placebo-controlled, double-blind
      study of the safety, tolerability, and bioeffect of REGN1500
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Day 1 to Day 106/126</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The primary endpoint in the study is the incidence and severity of treatment-emergent adverse events (TEAEs) through day 106/126 in participants treated with REGN1500.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of REGN1500</measure>
    <time_frame>Day 1 to Day 106/126</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum concentration of REGN1500 over time (summary statistics and PK parameters)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous (SC) injection of REGN1500 (Dose 1) or placebo SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC injection of REGN1500 (Dose 2) or placebo SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC injection of REGN1500 (Dose 3) or placebo SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous (IV) infusion of REGN1500 (Dose 4) or placebo IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion of REGN1500 (Dose 5) or placebo IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion of REGN1500 (Dose 6) or placebo IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN1500</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Body mass index 18.0 to 40.0 kg/m2, inclusive

          2. Normal standard 12-lead ECG

          3. Willing to refrain from the consumption of alcohol for 24 hours prior to each study
             visit

          4. Willing to consistently maintain his/her usual diet for the duration of the study

          5. Willing to refrain from strenuous exercise for the duration of the trial

          6. Willing and able to comply with clinic visits and study-related procedures

          7. Provide signed informed consent

          8. For sexually active men and women of childbearing potential, willingness to utilize
             adequate contraception and not become pregnant (or have their partner[s] become
             pregnant) during the full duration of the study.

        Exclusion Criteria:

          1. Any clinically significant abnormalities observed during the screening visit

          2. History of drug or alcohol abuse within 1 year of screening

          3. Receipt of another investigational drug or therapy within 30 days or at least 5
             half-lives (whichever is longer), of the investigational drug prior to the screening
             visit.

          4. Significant concomitant illness or history of significant illness such as cardiac,
             renal, neurological, endocrinological, metabolic or lymphatic disease, or any other
             illness or condition that may adversely affect the subjects participation in this
             study

          5. Known history of human immunodeficiency virus (HIV) antibody; and/or positive
             hepatitis B surface antigen (HBsAg), and/or positive hepatitis C antibody (HCV) at
             the screening visit

          6. Hospitalization for any reason within 60 days of screening

          7. History or presence of malignancy within 5 years prior to the screening visit (other
             than successfully treated non-metastatic cutaneous squamous cell or basal cell
             carcinoma, and/or localized carcinoma in situ of the cervix

          8. Any medical or psychiatric condition which, in the opinion of the investigator, would
             place the subject at risk, interfere with participation in the study or interfere
             with the interpretation of the study results

          9. Any subject who is the investigator or any sub-investigator, research assistant,
             pharmacist, study coordinator, or other staff directly involved in the conduct of the
             protocol, or family member of staff involved in the conduct of the protocol

         10. Pregnant or breast-feeding women

        (The inclusion/ exclusion criteria provided above are not intended to contain all
        considerations relevant to a patient's potential participation in this clinical trial).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 24, 2014</lastchanged_date>
  <firstreceived_date>December 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
